Home > > > Bradykinin Mediated Angioedema Market Size, Share, and Growth Opportunities 2025 –2032

Bradykinin Mediated Angioedema Market Size, Share, and Growth Opportunities 2025 –2032

Author : pooja chincholkar | Published On : 07 Apr 2026

Executive Summary Bradykinin Mediated Angioedema Market Size and Share Forecast

CAGR Value

  • The global bradykinin mediated angioedema market size was valued at USD 6.97 billion in 2025 and is expected to reach USD 10.21 billion by 2033, at a CAGR of 4.90% during the forecast period

By considering a definite base year and historic year, calculations in the Bradykinin Mediated Angioedema report have been carried out, which interprets the market performance by providing information about what the market definition, classifications, applications, and engagements are. Bradykinin Mediated Angioedema report also offers information about consumers’ demands, preferences, and their variable likings about particular products. To provide market definition, the report neatly researches market-driving factors and market restraints. A data triangulation method is employed in the report which has numerous components such as data mining, analysis of data variable effect on the market, and primary (industry expert) validation.

This Bradykinin Mediated Angioedema report also endows the company profile, product specifications, production value, manufacturer’s contact information, and market shares for the company. This market research report will definitely help in growing sales with new thinking, new skills, and innovative programs and tools. All the data, statistics, and information gathered to generate this report have been studied and analyzed with the established tools and techniques, such as SWOT analysis and Porter's Five Forces analysis. The study conducted in Bradykinin Mediated Angioedema Market report takes into account heterogeneous markets in accord with the requirements of Bradykinin Mediated Angioedema Market industry and scoops out the finest possible solutions and detailed information about the market trends.

Gain clarity on industry shifts, growth areas, and forecasts in our Bradykinin Mediated Angioedema Market report. Get your copy:
https://www.databridgemarketresearch.com/reports/global-bradykinin-mediated-angioedema-market

Bradykinin Mediated Angioedema Market Review

Segments

- By Product (C1 Esterase Inhibitors, Kallikrein Inhibitors, Bradykinin Receptor Antagonist, Others)
- By Type (Hereditary Angioedema, Acquired Angioedema)
- By Treatment (Medications, Surgery)
- By End User (Hospitals, Clinics, Others)

Bradykinin-mediated angioedema is a condition characterized by episodes of swelling in various parts of the body due to the overproduction of bradykinin, a peptide that promotes inflammation. The global market for bradykinin-mediated angioedema is segmented by product, type, treatment, and end-user. In terms of product, the market is divided into C1 esterase inhibitors, kallikrein inhibitors, bradykinin receptor antagonist, and others. C1 esterase inhibitors are the most commonly used treatment for hereditary angioedema, while kallikrein inhibitors are gaining traction in the market due to their effectiveness in managing acute attacks. The bradykinin receptor antagonist segment is also seeing growth as a promising treatment option for angioedema.

When looking at the types of bradykinin-mediated angioedema, there are two main categories: hereditary angioedema and acquired angioedema. Hereditary angioedema is a rare genetic condition that results in recurrent episodes of swelling, while acquired angioedema can be caused by various factors such as medications, autoimmune diseases, or infections. The market for bradykinin-mediated angioedema is also segmented by treatment options, including medications and surgery. Medications such as C1 esterase inhibitors and kallikrein inhibitors are the mainstay of treatment for angioedema, while surgery may be required in severe cases to remove excess fluid buildup.

In terms of end-users, the market for bradykinin-mediated angioedema includes hospitals, clinics, and other healthcare facilities. Hospitals are the primary point of care for patients experiencing severe angioedema attacks that require immediate medical intervention. Clinics play a crucial role in the long-term management of angioedema, providing follow-up care and monitoring for patients. Other healthcare facilities such as specialty treatment centers may also cater to individuals dealing with bradykinin-mediated angioedema, offering specialized services and expertise in managing this condition.

Market Players

- Pharming Group N.V.
- CSL Limited
- Ionis Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc.
- Shire (Now part of Takeda Pharmaceutical Company Limited)
- KalVista Pharmaceuticals
- Pharvaris
- Innovent Biologics, Inc.
- Attune Pharmaceuticals
- Adverum Biotechnologies

The global bradykinin-mediated angioedema market is highly competitive, with key players focusing on developing innovative treatments and expanding their market presence. Companies such as Pharming Group N.V., CSL Limited, and Ionis Pharmaceuticals, Inc. are leading the market with their established products for treating angioedema. Other players such as BioCryst Pharmaceuticals, Inc. and KalVista Pharmaceuticals are investing in research and development to introduce new therapies for bradykinin-mediated angioedema. Collaborations, partnerships, and acquisitions are common strategies employed by market players to strengthen their position and drive growth in this competitive landscape.

The global bradykinin-mediated angioedema market is witnessing significant growth and innovation driven by advancements in understanding the underlying mechanisms of this condition and the development of targeted therapeutic options. One area of focus for market players is the development of novel bradykinin inhibitors that can effectively block the inflammatory cascade triggered by excess bradykinin production. These inhibitors offer a promising approach to managing angioedema by specifically targeting the underlying cause of the condition. Additionally, the introduction of gene therapy approaches by companies such as Adverum Biotechnologies and Innovent Biologics, Inc. is opening up new possibilities for long-term treatment and potentially even curative solutions for hereditary angioedema.

Moreover, the market is witnessing a trend towards personalized medicine in the management of bradykinin-mediated angioedema. With a better understanding of the genetic and molecular factors that contribute to this condition, healthcare providers are increasingly tailoring treatment regimens to individual patients based on their unique characteristics and response to therapy. This personalized approach is not only enhancing the efficacy of treatments but also improving patient outcomes and quality of life.

Another key driver of market growth is the increasing awareness and diagnosis of bradykinin-mediated angioedema worldwide. Healthcare providers are becoming more adept at recognizing the signs and symptoms of this condition, leading to early intervention and appropriate management strategies. This heightened awareness is not only benefiting patients by ensuring timely treatment but also contributing to the overall expansion of the market as more cases are identified and treated.

In addition to traditional pharmaceutical interventions, the market for bradykinin-mediated angioedema is also exploring the potential of innovative treatment modalities such as RNA interference (RNAi) therapies and gene editing techniques. These cutting-edge approaches hold the promise of more targeted and precise treatment options that can address the underlying genetic abnormalities associated with hereditary angioedema. Market players like Ionis Pharmaceuticals, Inc. and Pharvaris are at the forefront of developing RNAi-based therapies that may revolutionize the treatment landscape for this condition.

Overall, the global bradykinin-mediated angioedema market is poised for substantial growth and transformation in the coming years, driven by increased research and development activities, strategic collaborations among industry players, and a growing emphasis on personalized and precision medicine approaches. As novel therapies continue to emerge and diagnostic capabilities improve, the market is expected to expand rapidly, providing new hope for patients living with this challenging and often debilitating condition.The bradykinin-mediated angioedema market is witnessing a paradigm shift towards personalized medicine, with a focus on developing innovative treatments that target the root cause of the condition. Market players are investing heavily in research and development to introduce novel bradykinin inhibitors that can effectively block the inflammatory cascade triggered by excess bradykinin production. By specifically targeting the underlying mechanisms of angioedema, these inhibitors offer a promising approach to managing the condition more effectively. Additionally, gene therapy approaches being explored by companies such as Adverum Biotechnologies and Innovent Biologics, Inc. are opening up new possibilities for long-term treatment and potentially curative solutions for hereditary angioedema.

Moreover, the market is witnessing a trend towards precision medicine in the management of bradykinin-mediated angioedema. Healthcare providers are increasingly customizing treatment regimens based on individual patients' genetic and molecular profiles to enhance treatment efficacy and improve patient outcomes. This personalized approach not only benefits patients but also contributes to the overall growth of the market as more tailored therapies are developed and adopted.

Increasing awareness and improved diagnostic capabilities are driving market growth by enabling early identification and intervention for bradykinin-mediated angioedema. Healthcare providers are becoming adept at recognizing the signs and symptoms of the condition, leading to timely treatment and appropriate management strategies. The heightened awareness surrounding angioedema is not only improving patient outcomes but also expanding the market as more cases are diagnosed and treated.

In addition to traditional pharmaceutical interventions, market players are exploring innovative treatment modalities such as RNA interference (RNAi) therapies and gene editing techniques. These cutting-edge approaches hold the promise of more targeted and precise treatment options that can address the genetic abnormalities associated with hereditary angioedema. Companies like Ionis Pharmaceuticals, Inc. and Pharvaris are at the forefront of developing RNAi-based therapies that have the potential to revolutionize the treatment landscape for bradykinin-mediated angioedema.

Overall, the global bradykinin-mediated angioedema market is poised for significant growth and transformation in the near future. With a focus on personalized medicine, innovation in therapeutic approaches, and increasing awareness of the condition, the market is expected to expand rapidly. Continued research and development efforts, strategic collaborations, and a shift towards precision medicine are driving forces that will shape the future of the bradykinin-mediated angioedema market, offering new hope for patients grappling with this challenging condition.

Uncover the company’s portion of market ownership
https://www.databridgemarketresearch.com/reports/global-bradykinin-mediated-angioedema-market/companies

Structured Market Research Questions for Bradykinin Mediated Angioedema Market

  • What is the present size of the global Bradykinin Mediated Angioedema industry?
  • What annual growth rate is projected for the Bradykinin Mediated Angioedema sector?
  • What are the main segment divisions in the Bradykinin Mediated Angioedema Market report?
  • Who are the established players in the global Bradykinin Mediated Angioedema Market?
  • What geographic areas are explored in the Bradykinin Mediated Angioedema Market report?
  • Who are the leading manufacturers and service providers for Bradykinin Mediated Angioedema Market?

Browse More Reports:

 Global Plasmapheresis Periprocedural Care Equipments Market
 Global Plenoptic Camera Market
 Global Pleural Effusion Market
 Global Pleural Effusions Treatment Market
 Global Pleuropulmonary Blastoma Treatment Market
 Global Point-Of-Care Ultrasound Systems (POCUS) Market
 Global Polyethylenimine Market
 Global Polymer Modified Cementitious Coatings Market
 Global Polyurethane Composites Market
 Global Pompe Disease Market
 Global Pompe Disease Treatment Market
 Global Portable Ultrasound Bladder Scanner Market
 Global Postal Packaging Market
 Global Potash Nitrate Fertilizer Market
 Global Power over Ethernet (PoE) Solutions Market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
Email:- [email protected]